| Cheng Xie | |
|---|---|
| Photo placeholder | |
| Affiliations | Fudan University |
| Country | China |
| H-index | 40 |
| Research Focus | Alzheimer's Disease |
| Mechanisms | Tau, Synaptic plasticity |
Cheng Xie is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Cheng Xie is a leading researcher in the field of neurodegenerative diseases, affiliated with Fudan University [1]. Their research focuses on Tau, Synaptic plasticity, with particular emphasis on Alzheimer's Disease [2]. With an h-index of 40, Xie is among the most cited researchers in the neuroscience field [3]. Xie's work spans multiple aspects of neurodegeneration, contributing to our understanding of the molecular mechanisms that underlie diseases such as
Alzheimer's Disease [1]. Their research group has made significant contributions to the fields of Tau, Synaptic plasticity,
publishing in high-impact journals including leading neuroscience journals [2]. Based at
Fudan University, Xie collaborates with researchers across multiple institutions worldwide, working to advance therapeutic strategies for neurodegenerative conditions [3].
Xie has developed research programs that bridge basic neuroscience, translational biomarker work, and clinical interpretation. Across appointments at Fudan University, their group has helped define how mechanistic discoveries are converted into robust disease models and clinically actionable hypotheses.
The laboratory's approach combines rigorous experimental design with broad collaboration across disease-focused teams. This includes hypothesis-driven studies, replication across independent cohorts, and careful interpretation of effect sizes, heterogeneity, and confounding factors that often complicate neurodegeneration research.
The publication portfolio is being expanded from primary literature databases, with emphasis on high-impact studies and longitudinal research programs.
Their program contributes to translational and mechanistic work in Alzheimer's Disease.
The lab emphasizes Tau to connect molecular findings with patient outcomes. The lab emphasizes Synaptic plasticity to connect molecular findings with patient outcomes.
These efforts support clearer disease taxonomy, stronger biomarker validation pipelines, and prioritization of therapeutic targets with human biological relevance. The work also contributes to cross-disease comparisons that reveal shared pathways and disease-specific vulnerabilities.
Current priorities in Xie's research ecosystem include improving reproducibility across cohorts, integrating multi-omic and longitudinal clinical datasets, and clarifying which biological signals are most predictive of near-term progression and treatment response. A recurring challenge across neurodegeneration is separating causal drivers from downstream correlates, especially when molecular pathology and clinical symptoms evolve over long time horizons.
Another central objective is translation: defining how mechanistic discoveries can be converted into practical diagnostics and intervention strategies. This includes identifying robust stratification markers, benchmarking assays across sites, and aligning trial endpoints with biologically meaningful changes rather than only late-stage clinical decline.
Collaborator network pending enrichment.
Ma T et al.. "Low-dose metformin targets the lysosomal AMPK pathway through PEN2." Nature (2022). DOI
Shen C et al.. "Associations of Social Isolation and Loneliness With Later Dementia." Neurology (2022). DOI
Li Y et al.. "The brain structure and genetic mechanisms underlying the nonlinear association between sleep duration, cognition and mental health." Nature aging (2022). DOI
Xie C et al.. "Amelioration of Alzheimer's Disease pathology by mitophagy inducers identified via machine learning and a cross-species workflow." Nature biomedical engineering (2022). DOI
Liu Z et al.. "Sec13 promotes oligodendrocyte differentiation and myelin repair through autocrine pleiotrophin signaling." The Journal of clinical investigation (2022). DOI
Zhang X et al.. "Pyroptosis-mediator GSDMD promotes Parkinson's Disease pathology via microglial activation and dopaminergic neuronal death." Brain, behavior, and immunity (2024). DOI
Xiong X et al.. "NAD+-boosting agent nicotinamide mononucleotide potently improves mitochondria stress response in Alzheimer's Disease via ATF4-dependent mitochondrial UPR." Cell death & disease (2024). DOI
Fang EF et al.. "A research agenda for ageing in China in the 21st century (2nd edition): Focusing on basic and translational research, long-term care, policy and social networks." Ageing research reviews (2020). DOI
Ma T et al.. "Low-dose metformin targets the lysosomal AMPK pathway through PEN2." Nature (2022). DOI: 10.1038/s41586-022-04431-8 PubMed: 35197629
Shen C et al.. "Associations of Social Isolation and Loneliness With Later Dementia." Neurology (2022). DOI: 10.1212/WNL.0000000000200583 PubMed: 35676089
Li Y et al.. "The brain structure and genetic mechanisms underlying the nonlinear association between sleep duration, cognition and mental health." Nature aging (2022). DOI: 10.1038/s43587-022-00210-2 PubMed: 37118065
Xie C et al.. "Amelioration of Alzheimer's Disease pathology by mitophagy inducers identified via machine learning and a cross-species workflow." Nature biomedical engineering (2022). DOI: 10.1038/s41551-021-00819-5 PubMed: 34992270
Liu Z et al.. "Sec13 promotes oligodendrocyte differentiation and myelin repair through autocrine pleiotrophin signaling." The Journal of clinical investigation (2022). DOI: 10.1172/JCI155096 PubMed: 35143418
Zhang X et al.. "Pyroptosis-mediator GSDMD promotes Parkinson's Disease pathology via microglial activation and dopaminergic neuronal death." Brain, behavior, and immunity (2024). DOI: 10.1016/j.bbi.2024.03.038 PubMed: 38552923
Xiong X et al.. "NAD+-boosting agent nicotinamide mononucleotide potently improves mitochondria stress response in Alzheimer's Disease via ATF4-dependent mitochondrial UPR." Cell death & disease (2024). DOI: 10.1038/s41419-024-07062-1 PubMed: 39394148
Fang EF et al.. "A research agenda for ageing in China in the 21st century (2nd edition): Focusing on basic and translational research, long-term care, policy and social networks." Ageing research reviews (2020). DOI: 10.1016/j.arr.2020.101174 PubMed: 32971255
Ma T et al.. "Low-dose metformin targets the lysosomal AMPK pathway through PEN2." Nature (2022). DOI
Shen C et al.. "Associations of Social Isolation and Loneliness With Later Dementia." Neurology (2022). DOI
Li Y et al.. "The brain structure and genetic mechanisms underlying the nonlinear association between sleep duration, cognition and mental health." Nature aging (2022). DOI
Xie C et al.. "Amelioration of Alzheimer's Disease pathology by mitophagy inducers identified via machine learning and a cross-species workflow." Nature biomedical engineering (2022). DOI
Liu Z et al.. "Sec13 promotes oligodendrocyte differentiation and myelin repair through autocrine pleiotrophin signaling." The Journal of clinical investigation (2022). DOI
Zhang X et al.. "Pyroptosis-mediator GSDMD promotes Parkinson's Disease pathology via microglial activation and dopaminergic neuronal death." Brain, behavior, and immunity (2024). DOI
Xiong X et al.. "NAD+-boosting agent nicotinamide mononucleotide potently improves mitochondria stress response in Alzheimer's Disease via ATF4-dependent mitochondrial UPR." Cell death & disease (2024). DOI
Fang EF et al.. "A research agenda for ageing in China in the 21st century (2nd edition): Focusing on basic and translational research, long-term care, policy and social networks." Ageing research reviews (2020). DOI
Ma T et al.. "Low-dose metformin targets the lysosomal AMPK pathway through PEN2." Nature (2022). DOI: 10.1038/s41586-022-04431-8 PubMed: 35197629
Shen C et al.. "Associations of Social Isolation and Loneliness With Later Dementia." Neurology (2022). DOI: 10.1212/WNL.0000000000200583 PubMed: 35676089
Li Y et al.. "The brain structure and genetic mechanisms underlying the nonlinear association between sleep duration, cognition and mental health." Nature aging (2022). DOI: 10.1038/s43587-022-00210-2 PubMed: 37118065
Xie C et al.. "Amelioration of Alzheimer's Disease pathology by mitophagy inducers identified via machine learning and a cross-species workflow." Nature biomedical engineering (2022). DOI: 10.1038/s41551-021-00819-5 PubMed: 34992270
Liu Z et al.. "Sec13 promotes oligodendrocyte differentiation and myelin repair through autocrine pleiotrophin signaling." The Journal of clinical investigation (2022). DOI: 10.1172/JCI155096 PubMed: 35143418
Zhang X et al.. "Pyroptosis-mediator GSDMD promotes Parkinson's Disease pathology via microglial activation and dopaminergic neuronal death." Brain, behavior, and immunity (2024). DOI: 10.1016/j.bbi.2024.03.038 PubMed: 38552923
Xiong X et al.. "NAD+-boosting agent nicotinamide mononucleotide potently improves mitochondria stress response in Alzheimer's Disease via ATF4-dependent mitochondrial UPR." Cell death & disease (2024). DOI: 10.1038/s41419-024-07062-1 PubMed: 39394148
Fang EF et al.. "A research agenda for ageing in China in the 21st century (2nd edition): Focusing on basic and translational research, long-term care, policy and social networks." Ageing research reviews (2020). DOI: 10.1016/j.arr.2020.101174 PubMed: 32971255
The study of Cheng Xie has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.